Publications by authors named "Paul Fishkin"

Claim this Profile
A
A multicenter phase 1/2 trial of lenalidomide and dose-adjusted EPOCH-R in MYC-associated DLBCL.
Kirk Cahill, James Godfrey, Chadi Nabhan, Justin Kline, Peter A Riedell, Paul A S Fishkin

Blood Adv· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Follow-Up of the RESORT Study (E4402): A Randomized Phase III Comparison of Two Different Rituximab Dosing Strategies for Low-Tumor Burden Follicular Lymphoma.
Brad S Kahl, Opeyemi A Jegede, Christopher Peterson, Lode J Swinnen, Thomas M Habermann, Paul A Fishkin

J Clin Oncol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas.
Ajay Major, Justin Kline, Theodore G Karrison, Paul A S Fishkin, Amy S Kimball

Haematologica· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.
Russell Z Szmulewitz, Cody J Peer, Abiola Ibraheem, Elia Martinez, Mark F Kozloff, Paul Fishkin

J Clin Oncol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling.
Alexa B Schrock, Shuyu D Li, Garrett M Frampton, James Suh, Eduardo Braun, Paul Fishkin

J Thorac Oncol· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma.
Randy F Sweis, Milica Medved, Shannon Towey, Gregory S Karczmar, Aytekin Oto, Paul Fishkin

Clin Genitourin Cancer· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concurrent EGFR Mutation and ALK Translocation in Non-Small Cell Lung Cancer.
Randy F Sweis, Sachdev Thomas, Bruce Bank, Paul Fishkin, Colin Mooney

Cureus· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II interventional study (N0337) of capecitabine in combination with vinorelbine and trastuzumab for first- or second-line treatment of HER2-positive metastatic breast cancer: a north central cancer treatment group trial.
Winston W Tan, Jacob B Allred, Muhammad Salim, Patrick Flynn, Paul A S Fishkin

Clin Breast Cancer· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction.
Nicholas W Choong, Ann M Mauer, Daniel C Haraf, Mark K Ferguson, Alan B Sandler, Paul A S Fishkin

Med Oncol· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report.
Thomas E Witzig, Paul Fishkin, Leo I Gordon, Stephanie A Gregory, Samuel Jacobs

Leuk Lymphoma· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB).
Aminah Jatoi, Kendrith Rowland, Jeff A Sloan, Howard M Gross, Paul A Fishkin

Cancer· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group.
David J Inwards, Paul A S Fishkin, David W Hillman, David W Brown, Stephen M Ansell

Cancer· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032.
James N Ingle, Vera J Suman, Kendrith M Rowland, Deepu Mirchandani, Albert M Bernath, Paul A S Fishkin

J Clin Oncol· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of dolastatin-10 in patients with advanced breast cancer.
Edith A Perez, David W Hillman, Paul A Fishkin, James E Krook, Winston W Tan

Invest New Drugs· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CPT-11 for bile-duct and gallbladder carcinoma: a phase II North Central Cancer Treatment Group (NCCTG) study.
Steven R Alberts, Paul A Fishkin, Lawrence J Burgart, Peter J Cera, Michelle R Mahoney

Int J Gastrointest Cancer· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis